Hospira
Hospira, Inc., a leading global provider of injectable drugs and infusion technologies, is headquartered in the United States. Founded in 2004, the company has established itself as a key player in the pharmaceutical and biotechnology industry, focusing on critical care and hospital products. With major operational regions across North America, Europe, and Asia, Hospira is renowned for its commitment to quality and innovation. The company offers a diverse range of core products, including sterile injectable medications, biosimilars, and advanced infusion systems, which are distinguished by their reliability and safety features. Hospira's market position is bolstered by its notable achievements in enhancing patient care and streamlining hospital operations, making it a trusted partner in healthcare settings worldwide.
DitchCarbon Score
How does Hospira's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hospira's score of 80 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hospira, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Pfizer Inc., which influences its climate commitments and initiatives. As a current subsidiary of Pfizer Inc., Hospira's climate strategies and targets are aligned with those of its parent company. Pfizer has set science-based targets (SBTi) to reduce its carbon footprint, which cascades down to Hospira. This includes commitments to renewable energy initiatives and participation in the CDP (formerly Carbon Disclosure Project) to enhance transparency in environmental impact. While specific reduction targets for Hospira are not detailed, the overarching goals from Pfizer aim to significantly lower emissions across all scopes, including Scope 1, 2, and 3. The commitment to sustainability is evident through initiatives like RE100 and the Race to Zero campaign, which further reinforce the company's dedication to addressing climate change. In summary, while Hospira does not provide specific emissions data, it is actively engaged in climate commitments through its affiliation with Pfizer Inc., focusing on reducing its environmental impact in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | - | - | - | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hospira is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
